Xenetic BioSciences Inc. (NASDAQ:XBIO) Stock Sees Solid Buying Interest: Buy Now?

August 11, 2021

Xenetic BioSciences Inc. (NASDAQ:XBIO) jumped 14%. Recently, the company signed a sale and purchased a definitive agreement to purchase 4.63 million of its common shares by a healthcare-focused institutional investor. The company is offering the shares at $2.7 per share in an at-the-market private placement under the Nasdaq rules. Equally, the company agreed to provide the investor share purchase warrants to buy 4.63 million common shares. Notably, the contracts have…

Read More >>

Xenetic Biosciences (NASDAQ:XBIO) Stock Sees High Volatility: How to Trade Now?

August 2, 2021

Biopharmaceutical company, Xenetic Biosciences (NASDAQ:XBIO), on July 31, 2021 closure of previously announced private placement. This would be with single healthcare-focused institutional investor for 4,629,630 shares of the common stock. Xenetic focuses on a personalized CAR T platform technology for targeting patient and tumor specific neoantigens. The proceeds will be about $12.5 million before deducting placement agent fees and other offering expenses.The company issued to investor warrants for buying 4,629,630…

Read More >>

Xenetic Biosciences Inc (NASDAQ:XBIO) Stock Slumps 23% On Profit Booking

July 31, 2021

The week did not end on the right note for Xenetic Biosciences Inc (NASDAQ:XBIO) as the biopharmaceutical firm saw its stock crash by as much as 23% on Friday. There was no fresh news about the company yesterday but earlier on in the week the company had made a key announcement that investors need to take a look into. This past Wednesday the company announced that it successfully completed the…

Read More >>